ATOSSA THERAPEUTICS INC. - COMMON STOCK

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

28 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

21 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

20 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

12 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

22 Jul 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

02 Jul 2024 16:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

28 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

17 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa to Present at the Sidoti Small-Cap Investor Conference

05 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

28 May 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

15 May 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

13 May 2024 08:50:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

07 May 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

29 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

15 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

11 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

09 Apr 2024 11:59:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

05 Apr 2024 09:58:53 By NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

04 Apr 2024 11:38:29 By NetDania Notify

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

01 Apr 2024 16:00:00 By Nasdaq GlobeNewswire